Shares of Ovid Therapeutc (NASDAQ:OVID) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $21.00 for the company and are expecting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also given Ovid Therapeutc an industry rank of 166 out of 265 based on the ratings given to its competitors.

A number of equities analysts have issued reports on the stock. William Blair assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. JMP Securities assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating and a $26.00 price objective on the stock. Cowen and Company assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. Finally, Citigroup Inc. assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set a “buy” rating and a $21.00 price objective on the stock.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/19/zacks-brokerages-set-21-00-price-target-for-ovid-therapeutc-ovid.html.

Shares of Ovid Therapeutc (NASDAQ:OVID) traded down 2.71% on Monday, reaching $12.90. 24,845 shares of the company traded hands. Ovid Therapeutc has a one year low of $10.71 and a one year high of $15.93. The company’s market capitalization is $272.86 million. The firm has a 50-day moving average price of $13.50 and a 200 day moving average price of $13.50.

Ovid Therapeutc (NASDAQ:OVID) last announced its quarterly earnings results on Tuesday, June 13th. The company reported ($3.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.87) by $2.61. Equities analysts forecast that Ovid Therapeutc will post ($3.27) EPS for the current fiscal year.

Ovid Therapeutc Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Get a free copy of the Zacks research report on Ovid Therapeutc (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.